Referenser

  1. Gillberg C. The ESSENCE in child psychiatry: Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations. Res Dev Disabil. 2010;31(6):1543-51.

  2. Wing L. Asperger's syndrome: a clinical account. Psychol Med. 1981;11(1):115-29.

  3. Helles A, Gillberg IC, Gillberg C, Billstedt E. Asperger syndrome in males over two decades: Quality of life in relation to diagnostic stability and psychiatric comorbidity. Autism. 2017;21(4):458-69.

  4. Adolfsson I. C-KG, Dahlström K., Fernell E.,. Svag begåvning – normalt, men inte problemfritt. Läkartidningen. 2002;99(16):1820-2.

  5. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434-42.

  6. Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021;11:04009.

  7. Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens E, et al. Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD. Am J Psychiatry. 2022;179(2):142-51.

  8. Skogli EW, Teicher MH, Andersen PN, Hovik KT, Øie M. ADHD in girls and boys--gender differences in co-existing symptoms and executive function measures. BMC Psychiatry. 2013;13:298.

  9. Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28(10):1059-88.

  10. Mowlem FD, Rosenqvist MA, Martin J, Lichtenstein P, Asherson P, Larsson H. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. Eur Child Adolesc Psychiatry. 2019;28(4):481-9.

  11. Socialstyrelsen. Fortsatt kraftig ökning av ADHD-diagnoser Stockholm: Socialstyrelsen; 2023 [Available from: https://www.socialstyrelsen.se/om-socialstyrelsen/pressrum/press/fortsatt-kraftig-okning-av-adhd-diagnoser/

  12. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562-75.

  13. Larsson H, Anckarsater H, Råstam M, Chang Z, Lichtenstein P. Childhood attention-deficit hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study of 8,500 twin pairs. J Child Psychol Psychiatry. 2012;53(1):73-80.

  14. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818.

  15. Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat Genet. 2023;55(2):198-208.

  16. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A. 2007;104(49):19649-54.

  17. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395(10222):450-62.

  18. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.

  19. Reale L, Bartoli B, Cartabia M, Zanetti M, Costantino MA, Canevini MP, et al. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017;26(12):1443-57.

  20. Shaw P, Stringaris A, Nigg J, Leibenluft E. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171(3):276-93.

  21. Gordon M, Antshel K, Faraone S, Barkley R, Lewandowski L, Hudziak JJ, et al. Symptoms versus impairment: the case for respecting DSM-IV's Criterion D. J Atten Disord. 2006;9(3):465-75.

  22. Socialstyrelsen. Konsekvenser för vuxna med diagnosen ADHD Stockholm: Socialstyrelsen; 2019 [Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/ovrigt/2019-6-21.pdf

  23. Cherkasova MV, Roy A, Molina BSG, Scott G, Weiss G, Barkley RA, et al. Review: Adult Outcome as Seen Through Controlled Prospective Follow-up Studies of Children With Attention-Deficit/Hyperactivity Disorder Followed Into Adulthood. J Am Acad Child Adolesc Psychiatry. 2022;61(3):378-91.

  24. Socialstyrelsen. Nationella riktlinjer 2024: Adhd och autism - Prioriteringsstöd till dig som beslutar om resurser i hälso- och sjukvården eller socialtjänsten Solna: Socialstyrelsen; 2024 [Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-riktlinjer/2024-3-8958.pdf

  25. Stahlberg O, Soderstrom H, Rastam M, Gillberg C. Bipolar disorder, schizophrenia, and other psychotic disorders in adults with childhood onset AD/HD and/or autism spectrum disorders. J Neural Transm (Vienna). 2004;111(7):891-902.

  26. Lichtenstein P, Halldner L, Zetterqvist J, Sjölander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006-14.

  27. Chang Z, Quinn PD, Hur K, Gibbons RD, Sjölander A, Larsson H, et al. Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. JAMA Psychiatry. 2017;74(6):597-603.

  28. Chang Z, Quinn PD, O'Reilly L, Sjölander A, Hur K, Gibbons R, et al. Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts. Biol Psychiatry. 2020;88(6):452-8.

  29. Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, et al. ADHD Medication and Substance-Related Problems. Am J Psychiatry. 2017;174(9):877-85.

  30. Schweren L, Hoekstra P, van Lieshout M, Oosterlaan J, Lambregts-Rommelse N, Buitelaar J, et al. Long-term effects of stimulant treatment on ADHD symptoms, social-emotional functioning, and cognition. Psychol Med. 2019;49(2):217-23.

  31. Swanson JM, Arnold LE, Molina BSG, Sibley MH, Hechtman LT, Hinshaw SP, et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry. 2017;58(6):663-78.

  32. Edvinsson D, Ekselius L. Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study. J Clin Psychopharmacol. 2018;38(4):370-5.

  33. Brikell I, Yao H, Li L, Astrup A, Gao L, Gillies MB, et al. ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases. Lancet Psychiatry. 2024;11(1):16-26.

  34. Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev. 2013;37(6):1162-71.

  35. Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, et al. Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders. J Child Adolesc Psychopharmacol. 2017;27(9):762-70.

  36. Ornoy A, Koren G. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. Curr Neuropharmacol. 2021;19(11):1794-804.

  37. Torgersen T, Gjervan B, Rasmussen K, Vaaler A, Nordahl HM. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD. Atten Defic Hyperact Disord. 2013;5(1):59-67.

  38. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408-14.

  39. Bejerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry. 2010;71(12):1590-7.

  40. Chang Z, Lichtenstein P, Halldner L, D'Onofrio B, Serlachius E, Fazel S, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878-85.

  41. Justitieombudsmannen. Kritik mot psykiatrin inom två regioner för regelmässiga kontroller genom urinprov och blodprov som villkor för att patienter ska kunna få viss utredning eller behandling Dnr: 6160-2022, 1112-2023 Stockholm: Riksdagens ombudsmän; 2023 [Available from: https://www.jo.se/app/uploads/resolve_pdfs/1573972_6160-2022.pdf

  42. Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D'Onofrio BM, et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry. 2023.

  43. Huang KL, Wei HT, Hsu JW, Bai YM, Su TP, Li CT, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiatry. 2018;212(4):234-8.

  44. Anorson N, Male I, Farr W, Memon A. Prevalence of autism in Europe, North America and Oceania, 2000-2020: A systematic review. European Journal of Public Health. 2021;31(Supplement_3).

  45. Brugha TS, Spiers N, Bankart J, Cooper SA, McManus S, Scott FJ, et al. Epidemiology of autism in adults across age groups and ability levels. Br J Psychiatry. 2016;209(6):498-503.

  46. Carroll LS, Owen MJ. Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med. 2009;1(10):102.

  47. Persico AM, Napolioni V. Autism genetics. Behav Brain Res. 2013;251:95-112.

  48. DiGuiseppi C, Hepburn S, Davis JM, Fidler DJ, Hartway S, Lee NR, et al. Screening for autism spectrum disorders in children with Down syndrome: population prevalence and screening test characteristics. J Dev Behav Pediatr. 2010;31(3):181-91.

  49. Bölte S, Girdler S, Marschik PB. The contribution of environmental exposure to the etiology of autism spectrum disorder. Cell Mol Life Sci. 2019;76(7):1275-97.

  50. Matson JL, Sipes M, Fodstad JC, Fitzgerald ME. Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder. CNS Drugs. 2011;25(7):597-606.

  51. Alfageh BH, Man KKC, Besag FMC, Alhawassi TM, Wong ICK, Brauer R. Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK. J Autism Dev Disord. 2020;50(2):625-33.

  52. Joshi G, Wilens T, Firmin ES, Hoskova B, Biederman J. Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. J Psychopharmacol. 2021;35(3):203-10.

  53. Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;2016(6):Cd009043.

  54. Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023;10(10):Cd011769.

Föregående sida
Behandling

Nästa sida
Tillbaka till kapitlets första sida